MATT ABERNETHY - 31 Jan 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Financial Officer
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
31 Jan 2026
Net transactions value
-$186,130
Form type
4
Filing time
03 Feb 2026, 18:06:21 UTC
Previous filing
30 May 2025
Next filing
17 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ABERNETHY MATT Chief Financial Officer 6027 EDGEWOOD BEND CT., SAN DIEGO /s/ Darin Lippoldt, Attorney-in-Fact 03 Feb 2026 0001724097

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $0 +2,437 +6.8% $0.000000 38,465 31 Jan 2026 Direct F1
transaction NBIX Common Stock Tax liability $186,130 -1,368 -3.6% $136.06 37,097 31 Jan 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Restricted Stock Unit Options Exercise $0 -2,437 -100% $0.000000 0 31 Jan 2026 Common Stock 2,437 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes an aggregate of 218 shares purchased on August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
F2 Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.
F3 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F4 This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,436 shares on January 31, 2023, vested as to 2,436 shares on January 31, 2024, vested as to 2,436 shares on January 31, 2025, and vested as to 2,437 shares on January 31, 2026, subject to the terms and conditions of the award.